First-line (1L) trastuzumab deruxtecan (T-DXd) regimens in advanced HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Exploratory analysis of baseline HER2-related biomarkers in DESTINY-Gastric03 (DG-03) Part 2

  • Janjigian, Yelena Y.
  • van Laarhoven, Hanneke
  • Rha, Sun Young
  • Kozlov, Vadim
  • Lee, Keun-Wook
  • ... Lee, Jeeyun
  • 외 16명
Citations

WEB OF SCIENCE

0
제목
First-line (1L) trastuzumab deruxtecan (T-DXd) regimens in advanced HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Exploratory analysis of baseline HER2-related biomarkers in DESTINY-Gastric03 (DG-03) Part 2
저자
Janjigian, Yelena Y.van Laarhoven, HannekeRha, Sun YoungKozlov, VadimLee, Keun-WookOh, Do-YounGravina, AdrianoRyu, Min-HeeRapatoni, LianeAntunes, LuisPietrantonio, FilippoShoji, HirokazuHofheinz, Ralf-DieterChenard-Poirier, MaximeChen, Li-TzongVasiliev, AleksandrKutukova, SvetlanaLambert, Arthur W.Yu, KunScott, MeganRabbie, RoyLee, Jeeyun
DOI
10.1158/1538-7445.AM2026-LB010
발행일
2026-04-17
유형
Meeting Abstract
저널명
Cancer Research
86
8
페이지
LB010 ~ LB010